Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo to Set Up Japan Company
March 8, 2010
- NDA for Cancer Pain Killer KW-2246 Submitted in Japan: Kyowa Kirin
March 8, 2010
- Dr Haranaka Opens Campaign Office for JMA Election
March 8, 2010
- Takeda Loses Sole Lead Among Admired Companies
March 8, 2010
- Novartis, Ono Apply for Rivastigmine Patch for AD in Japan
March 8, 2010
- NHI Program's Deficit Decreased in FY2008
March 8, 2010
- Eisai Launches Revovir in the Philippines
March 8, 2010
- Janssen Applies for Galantamine for AD in Japan
March 8, 2010
- New HIV-Infected Persons Down to 1,008 in 2009
March 8, 2010
- Daiichi Sankyo to Educate People about Vaccines
March 8, 2010
- Korosho's Study Group Issues Preliminary Report on Regenerative Cell Therapy
March 8, 2010
- Humira More Convenient for Psoriasis than Remicade: Prof. Nakagawa
March 8, 2010
- AnGes MG Obtains Patent on eNOS-Induced Angiogenesis
March 8, 2010
- Hospital Managers' Understanding of New Pricing System Essential: Korosho
March 8, 2010
- GLP-1 Agonists More Convenient than DPP-4 Inhibitors: Prof Kadowaki
March 8, 2010
- Paltac to Be Listed on TSE, OSE
March 8, 2010
- NEW PRODUCTS
March 8, 2010
- UBC Opens Its Own Office in Tokyo
March 8, 2010
- 9 Products, Including Pfizer's Lyrica, Recommended for Approval
March 8, 2010
- Daiichi Sankyo to Embark on Generics Business in Japan
March 8, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…